Skip to main content
. 2022 May 17;45(9):1719–1727. doi: 10.1007/s40618-022-01809-3

Table 3.

Anthropometric, clinical, and biochemical variables among phenotypes of pre-diabetes

n = 1549 No pre-diabetes (n = 1121) Isolated IFG (n = 83) Isolated IGT (n = 78) Isolated IA1c (n = 177) ≥ 2 phenotypes (n = 90)
Male gender, n (%) 563 (50) 52 (63)a 32 (41) 87 (49) 40 (44)
Prepubertal stage, n (%) 162 (14) 10 (12) 4 (5)a 17 (10)a 7 (8)
Family history, n (%) 586 (52) 44 (53) 54 (69)b 77 (44) 43 (48)
Age (years) 11.5 ± 2.7 11.8 ± 2.6 12.2 ± 2.4 11.5 ± 2.5 12.4 ± 2.6
BMI, kg/m2 30.7 ± 5.4 31.7 ± 6.0 31.0 ± 5.3 31.2 ± 6.1 32.4 ± 6.2b
BMI-SDS 2.3 ± 0.6 2.4 ± 0.6 2.3 ± 0.6 2.3 ± 0.6 2.5 ± 0.6b
G0, (mg/dL) 85.8 ± 8.1 103.9 ± 4.0c 89.0 ± 7.2c 87.5 ± 7.2 102.7 ± 8.8c
G120, (mg/dL) 105.2 ± 15.6 117.3 ± 13.1c 153.3 ± 13.2c 109.8 ± 16.2c 139.8 ± 26.7c
HbA1c (mmol/mol) 33.0 ± 3.7 34.3 ± 2.9b 33.2 ± 3.4 40.3 ± 1.6c 40.1 ± 2.7c
HbA1c (%) 5.2 ± 0.3 5.3 ± 0.3b 5.2 ± 0.3 5.8 ± 0.1c 5.8 ± 0.2c
I0 (µUI/mL) 16.1 (11.4–23.7) 17.9 (12.5–25.9) 20.4 (13.7–34.1)c 19.3 (12.8–26.6) 24.8 (14.6–36.3)c
HOMA-IR 3.4 (2.3–4.9) 4.5 (3.1–6.8)c 4.5 (3.1–7.3)c 4.1 (2.8–5.9) 6.2 (3.8–9.0)c
1/I0 (µUI/mL) 0.06 (0.04–0.09) 0.06 (0.04–0.08) 0.05 (0.03–0.07)c 0.05 (0.04–0.08) 0.04 (0.03–0.07)c
Cholesterol, (mg/dL) 154.1 ± 29.4 154.1 ± 33.5 154.8 ± 30.4 156.3 ± 27.9 155.1 ± 25.5
HDL C (mg/dL) 48.1 ± 10.5 44.2 ± 7.9c 43.2 ± 7.3c 44.3 ± 7.4c 44.3 ± 10.3c
Triglycerides (mg/dL) 78.0 (61.0–102.0) 86.0 (60.0–108.0) 87.0 (66.0–115.0) 89.0 (69.0–112.5)b 88.0 (67.0–111.3)
TG/HDL ratio 1.7 (1.2–2.3) 2.0 (1.3–2.6) 2.0 (1.5–2.7) c 2.0 (1.4–2.8)c 2.0 (1.5–2.7)c
TC/HDL ratio 3.3 ± 0.9 3.6 ± 0.8 3.7 ± 1.0c 3.6 ± 0.8c 3.6 ± 0.9c
Systolic BP (mmHg) 113.1 ± 13.8 114.6 ± 12.9 115.6 ± 14.8 112.4 ± 14.8 117.7 ± 12.7
Diastolic BP (mmHg) 67.6 ± 9.4 69.1 ± 9.5 66.6 ± 9.3 66.7 ± 9.3 71.8 ± 9.8

Data are expressed as mean ± standard deviation, median (IQ range), n (%)

aP < 0.05 vs no pre-diabetes

bP < 0.025 vs no pre-diabetes

cP < 0.001 vs no pre-diabetes